The Effect of Vaccine Type and SARS-CoV-2 Lineage on Commercial SARS-CoV-2 Serologic and Pseudotype Neutralization Assays in mRNA Vaccine RecipientsmRNA 백신 수혜자의 상업용 SARS-CoV-2 혈청학적 및 유사형 중화 분석에 대한 백신 유형 및 SARS-CoV-2 계통의 효과Article Published on 2022-04-272022-09-11 Journal: Microbiology Spectrum [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] affected Alpha anti-S anti-S antibody Anti-SARS-CoV-2 S Anti-spike anti-spike antibodies anti-spike antibody Antibody testing approach association Beta Beta variant BNT162b2 CDC Characteristics Cohort collected Concentration correlated correlation COVID-19 infection Day determine difficulty Effect Elecsy enrolled epidemiological evaluated Gamma healthy Immunity immunity after vaccination immunogenicity individuals Interpretation interval Level Lower marker mRNA mRNA vaccine mRNA vaccines mRNA-1273 mRNA-1273 vaccine Neutralization assay Neutralizing activity neutralizing antibody neutralizing titers pseudotype receiving recipient recipients recommendation recruited Roche SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 variant SARS-CoV-2 variants serologic serologic assay serologic assays serology serum significantly higher Support surrogate Type vaccinated individual vaccination Vaccine variable variant were measured wild-type WT strain [DOI] 10.1128/spectrum.00211-22 PMC 바로가기 [Article Type] Article
Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variantsBA.1 및 BA.2 Omicron 변이체에 대한 Pfizer/BioNTech SARS-CoV-2 mRNA 3차 부스터 백신 용량의 안전성 및 면역원성Clinical and Translational Article Published on 2022-04-262022-09-14 Journal: Med (New York, N.Y.) [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, [키워드] Abstract adverse event AMED anti-spike antibody BA.1 BA.1.1 BA.2 BNT162b2 mRNA vaccine booster booster vaccination Booster vaccine breadth changes in Context cross-reactivity cytokine cytokine signature Delta dose evaluate evaluated finding funding groups healthcare worker Humoral immunity immunogenicity increase increase in individual Japan Live virus microneutralization mRNA mRNA vaccination Mutation neutralization neutralization ability Neutralization antibody neutralization titer Neutralizing Neutralizing antibodies neutralizing antibody no significant difference omicron Pfizer/BioNTech robust Safe Safety SARS-CoV-2 SARS-CoV-2 variants second vaccination sera significantly lower Spike protein subvariant supported the spike protein vaccination Vaccine vaccine dose Vaccine-induced immunity vaccinee variant variant of concern variants variants of concern VoC VOCs [DOI] 10.1016/j.medj.2022.04.013 PMC 바로가기 [Article Type] Clinical and Translational Article
Immune Response to Third Dose BNT162b2 COVID-19 Vaccine Among Kidney Transplant Recipients-A Prospective Study신장 이식 환자의 3차 접종 BNT162b2 COVID-19 백신에 대한 면역 반응-전향적 연구Article Published on 2022-04-212022-09-12 Journal: Transplant International [Category] COVID19(2023년), SARS, 진단, [키워드] 95% confidence interval anti-spike antibody antibody Antibody Response BNT162b2 cellular cellular response conducted control group controls COVID-19 COVID-19 vaccine Cutoff demonstrated dose evaluate evaluated healthcare humoral identify immune response Immunosuppression immunosuppression reduction kidney transplant recipient kidney transplant recipients kidney transplant recipients. log mRNA vaccine Multivariate analysis Odds ratio Participants Primary outcome Prospective Prospective Study reduction remained response Result SARS-CoV-2 second dose seronegative subset T-cell Response Transplant vaccination Vaccine vaccine dose variable [DOI] 10.3389/ti.2022.10204 PMC 바로가기 [Article Type] Article
The effect of immunization with inactivated SARS-CoV-2 vaccine (CoronaVac) and/or SARS-CoV-2 infection on antibody levels, plasmablasts, long-lived-plasma-cells, and IFN-γ release by natural killer cells비활성화된 SARS-CoV-2 백신(CoronaVac) 및/또는 SARS-CoV-2 감염이 항체 수준, 형질모세포, 수명이 긴 형질 세포 및 자연 살해 세포에 의한 IFN-γ 방출에 미치는 영향Article Published on 2022-04-202022-09-11 Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] anti-S anti-SARS-CoV-2 spike protein anti-spike antibody antibody Antibody Response B cell CD138 CD19 CD27 Cell CoronaVac COVID-19 detectable dose Elecsy elicited ELISA kit evaluated flow cytometry four groups Germinal center group groups HCW HCWs healthcare worker Healthcare workers IAV IFN-gamma IFN-γ immunization inactivated Inactivated vaccine interferon gamma İstanbul Killer cell long-lived plasma cell long-lived plasma cells Lymph node lymph nodes median memory B cell memory B cells Migration natural infection natural killer natural killer cell no difference not differ patients percentage phenotype Plasma cells plasmablast plasmablasts qPCR RT-PCR SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccine significantly higher significantly lower Spike protein study groups Test the antibody response the study group Turkey uninfected Vaccine Version virion was performed were measured Whole virion inactivated vaccine. [DOI] 10.1016/j.vaccine.2022.03.001 PMC 바로가기 [Article Type] Article
An Observational Cohort Study on the Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and B.1.1.7 Variant Infection in Healthcare Workers by Antibody and Vaccination Status중증급성호흡기증후군 코로나바이러스 2(SARS-CoV-2) 감염 및 B.1.1.7 항체 및 백신 접종 상태에 따른 의료 종사자의 변이 감염 발생률에 대한 관찰 코호트 연구Observational Study Published on 2022-04-092022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] COVID19(2023년), SARS, 변종, 임상, 치료기술, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adjusted age anti-spike antibodies anti-spike antibody antibody B.1.1.7 B.1.1.7 variant BNT162b2 ChAdOx1 ChAdOx1 nCoV-19 Chain Reaction changes in confidence interval coronavirus coronavirus 2 detectable dose doses evade Evidence evidence of HCW HCWs healthcare healthcare worker Healthcare workers Immunity incidence incidence rate Infection investigated longitudinal cohort study natural natural immunity natural infection no evidence of Oxford-AstraZeneca pandemic PCR-positive Pfizer-BioNTech Poisson regression polymerase chain polymerase chain reaction provided rate ratio reduced respiratory resulting robust S-gene SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant SARS-CoV-2 variants Sequencing seronegative seropositive Seropositivity severe acute respiratory syndrome Coronavirus Sex Single-dose status symptomatic symptomatic and asymptomatic symptomatic infection United Kingdom vaccination Vaccine vaccine dose Vaccine-induced immunity whole genome Whole genome sequencing without symptom worker [DOI] 10.1093/cid/ciab608 PMC 바로가기 [Article Type] Observational Study
Response to Severe Acute Respiratory Syndrome Coronavirus 2 Initial Series and Additional Dose Vaccine in Patients With Predominant Antibody DeficiencyOriginal Article Published on 2022-04-022023-06-16 Journal: The journal of allergy and clinical immunology. In [Category] COVID19(2023년), MERS, SARS, [키워드] Additional dose anti-nucleocapsid antibody anti-spike antibody COI, Cutoff index common variable immunodeficiency COVID-19 COVID-19, Coronavirus disease 2019 CVID CVID, Common variable immunodeficiency Humoral immunodeficiency Hypogammaglobulinemia IgG subclass deficiency Neutralization assay PAD, Predominant antibody deficiency Predominant antibody deficiency SAD, Specific antibody deficiency SARS-CoV-2 SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2 specific antibody deficiency vaccine response [DOI] 10.1016/j.jaip.2022.03.017 PMC 바로가기 [Article Type] Original Article
Multisystem Inflammatory Syndrome in Adult after First Dose of mRNA VaccinemRNA 백신 1차 접종 후 성인의 다기관 염증 증후군Case Reports Published on 2022-04-012022-09-11 Journal: Emerging Infectious Diseases [Category] COVID19(2023년), SARS, 치료법, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 anti-nucleocapsid antibody Anti-spike anti-spike antibody coronavirus coronavirus disease Corticosteroids COVID-19 COVID-19 vaccination cytokine cytokine profile Diagnosis first dose Hyperinflammatory hyperinflammatory state Inflammatory Japan MIS-A mRNA Multisystem inflammatory syndrome Myocardial myocardial injury Noninvasive ventilation receiving Respiratory failure SARS-CoV-2 serologic test severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 suggested syndrome treated Trigger vaccination Vaccine [DOI] 10.3201/eid2804.212585 PMC 바로가기 [Article Type] Case Reports
SARS-CoV-2 infection in dialysis and kidney transplant patients: immunological and serological response투석 및 신장 이식 환자의 SARS-CoV-2 감염: 면역학적 및 혈청학적 반응Article Published on 2022-04-012022-09-11 Journal: Journal of Nephrology [Category] COVID19(2023년), SARS, 치료법, [키워드] alteration anti-spike antibodies anti-spike antibody anti-spike antibody response B cells B-cell baseline baseline characteristics CD4 CD8 chemokine chemokines controls COVID-19 cytokine Cytokines DCs dendritic cell dialysis expression groups healthy subject healthy subjects Hemodialysis high mortality rate Hospitalization IFN-α IL10 IL6 immunological immunology innate immune system involved kidney transplant kidney transplant recipient kidney transplant recipients lymphocyte Lymphocyte subsets Lymphocytes moderate-severe monocyte Monocyte activation monocyte HLA-DR neutrophil neutrophil recruitment Patient patients patients with COVID-19 populations proportion SARS-CoV-2 SARS-COV-2 infection serological response severe disease symptom onset T cells terminally differentiated the disease two groups uninfected was increased were measured [DOI] 10.1007/s40620-021-01214-8 PMC 바로가기 [Article Type] Article
SARS COV-2 anti-nucleocapsid and anti-spike antibodies in an emergency department healthcare worker cohort: September 2020 – April 2021응급실 의료 종사자 집단의 SARS COV-2 항뉴클레오캡시드 및 항스파이크 항체: 2020년 9월 - 2021년 4월Article Published on 2022-04-012022-09-11 Journal: The American journal of emergency medicine [Category] COVID19(2023년), MERS, SARS, 진단, 치료법, [키워드] 95% CI age anti-spike antibodies anti-spike antibody antibody antibody level antibody levels Antibody Response Antigen baseline BNT162b2 Breakthrough infection breakthrough infections conducted Course COVID-19 infection decrease described emergency department examined Factor Healthcare system healthcare worker IgG antibodies IgG antibody immunogenicity incidence Infection mRNA mRNA-1273 nucleocapsid nucleocapsid antigen participant positive predictor prospective cohort study reduced SARS-CoV-2 SARS-CoV-2 antibodies SARS-COV-2 infection SARS-CoV-2 nucleocapsid SARS-CoV-2 spike antigen seronegative participant strained tested the antibody response the SARS-CoV-2 threshold vaccination Vaccine Vaccine immunogenicitiy. were measured [DOI] 10.1016/j.ajem.2022.01.055 PMC 바로가기 [Article Type] Article
IgG anti-spike antibody levels in healthcare workers with and without prior COVID-19 up to 3 months after BNT162b2 vaccinationBNT162b2 백신 접종 후 최대 3개월까지 이전 COVID-19 유무에 관계없이 의료 종사자의 IgG 안티 스파이크 항체 수준Article Published on 2022-04-012022-09-12 Journal: Diagnostic microbiology and infectious disease [Category] COVID19(2023년), SARS, 진단, [키워드] Anti-spike anti-spike antibody Antibody Response BNT162b2 COVID-19 COVID-19 testing dose HCW healthcare worker IgG immunoassay Mild mRNA vaccine natural infection of BNT162b2 SARS-CoV-2 significantly spike uninfected vaccination [DOI] 10.1016/j.diagmicrobio.2022.115638 PMC 바로가기 [Article Type] Article